Рет қаралды 2,490
Two phase III studies presented at the recent Digestive Disease Week (DDW) virtual meeting evaluated the safety and efficacy of risankizumab (Skyrizi), an anti-interleukin (IL)-23 therapy, in adults with moderate to severe Crohn's disease.
In this final of four exclusive roundtable episodes, MedPage Today has brought together three leaders in the field: moderator Jason K. Hou, MD, of Baylor College of Medicine in Houston, is joined by Shirley Cohen-Mekelburg, MD, of Michigan Medicine in Ann Arbor, and Jill Gaidos, MD, of Yale School of Medicine in New Haven, Connecticut, for a discussion on the encouraging findings and the possible implications for clinical practice.